Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
about
Upcoming translational challenges for uveal melanomaTrametinib: a MEK inhibitor for management of metastatic melanomaPathways and therapeutic targets in melanomaCombined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.The genetics of uveal melanoma: current insightsARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaUveal melanoma: epidemiology, etiology, and treatment of primary disease.Melanoma epidemiology, biology and prognosis.A molecular revolution in uveal melanoma: implications for patient care and targeted therapySystematic genomic and translational efficiency studies of uveal melanoma.Understanding the biology of melanoma and therapeutic implicationsThe phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Current and emerging treatment options for uveal melanoma.Positron emission tomography and functional characterization of a complete PBR/TSPO knockout.Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Biology of advanced uveal melanoma and next steps for clinical therapeutics.Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.Subcellular distribution patterns and elevated expression of GNA11 and GNA14 proteins in the lungs of humans with pulmonary arterial hypertension.Combined PKC and MEK inhibition for treating metastatic uveal melanomaParacrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal MelanomaTherapeutic interventions to disrupt the protein synthetic machinery in melanomaPatient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Melanoma mutagenesis and aberrant cell signaling.Latest developments in the biology and management of uveal melanoma.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Profile of selumetinib and its potential in the treatment of melanoma.Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.Toward precision medicine in glioblastoma: the promise and the challenges.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
P2860
Q26778535-9DEA491F-F7D5-40F5-A4F5-01165A4C97F9Q26782976-F9DF0AC1-B35D-4DB2-B17E-9D2054459DA4Q26865736-E246573C-8A41-4A12-AD77-6BCDC9B2D358Q27852093-2E28BC8E-BF84-4857-A411-3EC0D2DED6EDQ27852827-55E6D210-09FB-4E13-BE97-4CD4279172E9Q27853021-4F1C42D0-9426-449C-8F90-2A7244BCEE1EQ27853217-D0BECEC1-C7D4-4792-BB21-A576D51C3FC5Q28073150-3DBC0370-055E-41CC-A0BD-8FC86D74F11FQ28115305-5E2A91AB-20F7-4F79-BF4E-B310738E6209Q30235934-D39E9000-F353-46CC-AC83-D6AAFBEE48A4Q33698718-834CECE2-50B8-4124-8A74-AE839B637431Q33717375-A11E3B91-3613-4D56-AA5F-F4D62BE76442Q33778295-3286192E-64BC-4C18-9FE8-9158E82D9269Q33978378-D94235B6-0B50-454B-8154-94B3808ADC12Q34096861-C85196E2-9FC2-41A7-A43E-38AAE220C971Q34365949-C86E98DA-F029-4908-9595-8C027D28D454Q34655878-6A26E137-4DD1-42C3-9BB1-9FB79D28F09BQ34677691-9291F69E-39BD-4B7C-8F15-98992FCEED44Q34928118-918F203F-4183-4580-8D34-A34BA575FA23Q35079709-DF8323A0-EA0D-4724-87E2-1E3982488E50Q35097186-EA28FFC5-CF1A-4B21-B8C8-CAF85DD6D726Q35163048-98685FFC-940B-4145-94D7-548F4D3B35B1Q35168515-CB540437-BBD9-4D1C-B373-7A731FFA34AFQ35812275-E1C4D315-DE16-4DB4-B53C-C3BA32B59CC8Q36473355-29ED8A9E-F66D-454F-8005-3EF534383E97Q37040664-29900BC3-E5D8-4D75-B906-061F72CD682DQ37058301-31D19AD0-3093-4E62-84B6-C3763EB5F1FDQ37269087-81018A46-A5CA-40ED-AC88-A6E1CAF42235Q37582083-1CBA7A74-FBE7-456E-AA95-E2E8F0E2FFC9Q38096413-506196E0-D421-430D-9F7D-18F7A685DF69Q38146707-4B0EE504-9A5F-40B8-BAD6-2AA8EBF1A248Q38152310-F9B7976A-92CF-4E92-A436-188C4669D79BQ38185688-DCE2EE48-B49F-4627-BF9C-B23F559D46FEQ38219616-FF747231-BA13-443B-9D13-ED86DD2AC365Q38256348-A62BA7C4-D280-4C99-B0C4-2F26DF67E83EQ38297995-D74DF85B-5A3C-4A20-9455-E6802FB0B726Q38454659-5723F851-7F66-4BA3-9F3C-86F369F78F77Q38646057-0A3E9CC5-0121-45C2-8542-2271896A9B9FQ38704201-E01D167C-7ACD-41DA-B9CF-DCF57509D9DAQ38718726-CE3E615E-3E08-4A3B-99D6-FA48B9FE2C3F
P2860
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@en
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@nl
type
label
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@en
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@nl
prefLabel
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@en
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@nl
P2093
P2860
P1476
Combination small molecule MEK ...... Q- and GNA11-dependent manner.
@en
P2093
Bita Esmaeli
Brendan C Hayes
Gregory Lizee
Jahan S Khalili
Michael A Davies
Scott E Woodman
Xiaoxing Yu
P2860
P304
P356
10.1158/1078-0432.CCR-11-3227
P407
P50
P577
2012-06-25T00:00:00Z